Cardioprotective approaches when prescribing iSGLT-2
Abstract
Background. Sodium-Glucose Cotransporter-2 (NGLT-2) inhibitors have gained significant attention for their cardioprotective properties. This review explores the cardiovascular benefits of NGLT-2 inhibitors, particularly their impact on heart health in patients with comorbidities such as type 2 diabetes and heart failure. The primary objective is to evaluate the mechanisms and effectiveness of these inhibitors in improving cardiovascular outcomes.
Methods. A comprehensive review of relevant literature was conducted, focusing on recent studies, including clinical trials and meta-analyses, to assess the impact of NGLT-2 inhibitors on heart failure, diabetes, and associated cardiovascular events. The review examines various approaches related to the use of NGLT-2 inhibitors in treating cardiovascular conditions.
Key Content and Findings. NGLT-2 inhibitors have been shown to significantly reduce the risk of cardiovascular events, including heart failure hospitalizations and mortality. Their mechanisms of action include improving glucose control, reducing kidney burden, and mitigating endothelial dysfunction. The review highlights these mechanisms and the clinical benefits in treating patients with heart failure and type 2 diabetes.
Conclusion. NGLT-2 inhibitors represent a valuable treatment option for improving heart health in patients with type 2 diabetes and heart failure. Further research is needed to optimize their use and fully understand their underlying mechanisms.
About the Authors
List of references
Peripech N.B., Mikhaylova I.E., Sodium-glucose cotransporter 2 inhibitors: A successful pursuit of two hares, Russian Cardiology Journal, 2021, S2, 54–62, 10.15829/1560-4071-2021-4534.
Khalimov Y.Sh., Agafonov P.V., Kuzmich V.G., The role and place of dapagliflozin in the management of type 2 diabetes mellitus: From theory to practice, Medical Council, 2017, 3, 22–30, 10.21518/2079-701X- 2017-3-22-30.
Petunina N.A., The modern sodium-glucose cotransporter 2 inhibitor – ertugliflozin, Medical Council, 2023, 17, 06, 234–240, 10.21518/ms2022-032.
Galiero R., Caturano A., Vetrano E., Precision medicine in type 2 diabetes mellitus: Utility and limitations, Diabetes Metab Syndr Obes, 2023, 16, 3669–3689, 10.2147/DMSO.S390752.
Jensen J., Omar M., Kistorp C., Empagliflozin in heart failure patients with reduced ejection fraction: A randomized clinical trial (Empire HF), Trials, 2019, 20, 01, 374, 10.1186/s13063-019-3474-5.
Chwal B.C., Dos Reis R.C. P., Schmidt M.I., Achievement of treatment goals and mortality in individuals with diabetes: The ELSA-Brasil study, J Clin Med, 2023, 12, 024, 7663, 10.3390/jcm12247663.
McGuire D.K., Shih W.J., Cosentino F., Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis, JAMA Cardiol, 2021, 6, 02, 148–158, 10.1001/jamacardio.2020.4511.
Chen J.Y., Pan H.C., Shiao C.C., Wu V.C., Impact of SGLT2 inhibitors on patient outcomes: A network meta-analysis, Cardiovasc Diabetol, 2023, 22, 01, 290, 10.1186/s12933-023-02035-8.
Rawshani A., Rawshani A., Franze´n S., Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 2018, 379, 07, 633–644, 10.1056/NEJMoa1800256.
Petrie M.C., Verma S., Docherty K.F., Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes, JAMA, 2020, 323, 014, 1353–1368, 10.1001/jama.2020.1906.
Vaduganathan M., Docherty K.F., Solomon S.D., NGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomized controlled trials, Lancet, 2022, 400, 010354, 757–767, 10.1016/S0140-6736(22)01429-5.
Talha K.M., Butler J., Greene S.J., Fonarow G.C., Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US, JAMA Cardiol, 2023, 8, 01, 66–73, 10.1001/jamacardio.2022.4348.
Neal B., Perkovic V., Mahaffey K.W., Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 2017, 377, 07, 644–657, 10.1056/NEJMc1712572.
Sano M., Takei M., Shiraishi Y., Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys, J Clin Med Res, 2016, 8, 012, 844–847, 10.14740/jocmr2760w.
Lam C.S., Chandramouli C., Ahooja V., NGLT-2 inhibitors in heart failure: Current management, unmet needs, and therapeutic prospects, J Am Heart Assoc, 2019, 8, 020, e013389, 10.1161/JAHA.119.013389.
Zinman B., Wanner C., Lachin J.M., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 2015, 373, 022, 2117–2128, 10.1056/NEJMoa1504720.
Sakai T., Miura S., Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction: Novel prospective cohort study, Circ Rep, 2019, 1, 07, 286–295, 10.1253/circrep.CR-19-0018.
Levine M.J., Empagliflozin for type 2 diabetes mellitus: An overview of phase 3 clinical trials, Curr Diabetes Rev, 2017, 13, 04, 405–423, 10.2174/1573399812666160613113556.
McGuire D.K., Shih W.J., Cosentino F., Charbonnel B., Cherney D.Z. I., Dagogo-Jack S., Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis, JAMA Cardiol, 2021, 6, 148–158, 10.1001/jamacardio.2020.4511.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.